Filing Flows › Cytek Biosciences (CTKB) › Stock forecast & fair value
Cytek Biosciences (CTKB) stock forecast and price target
Cytek Biosciences (CTKB) trades at $5.83. 3 analysts' median price target is $6.00 (+3%), from $5.00 to $7.50.
Cytek Biosciences' latest quarter
Cytek Biosciences, Q3 2026: revenue $53.2M (+2% year over year), operating margin -15.8%, net loss $6.1M, operating cash flow −$4.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for CTKB stock?
The median of 3 analysts' 12-month targets is $6.00, +3% from $5.83; the range is $5.00 to $7.50. The average rating is none.
Does Cytek Biosciences usually beat earnings estimates?
It beat the consensus EPS estimate in 20% of the quarters on record.
Is CTKB stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.